IP Library Granted Patent US 8,198,323
Granted Patent B2
US 8,198,323 · App. 12/758,462 · Granted Jun 12, 2012

Curcumin analogues and uses thereof

Assignees: The University of North Carolina at Chapel Hill; The University of Rochester Medical Center; Androscience Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,198,323
App. No.
12/758,462
Granted
Jun 12, 2012
Kind
B2
Abstract

The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.

Claims (17)

1. A method of treating an androgen related cancer comprising administering to a subject in need thereof a treatment effective amount of a compound having the following structure:

or a pharmaceutical acceptable salt thereof, where said androgen related cancer is selected from the group consisting of skin cancer, small cell lung cancer, esophageal cancer, stomach cancer, colon cancer, breast cancer, endometrial cancer, ovarian cancer, liver cancer and prostate cancer.

2. The method according to claim 1 , wherein said cancer is prostate cancer.

3. The method according to claim 1 , wherein said cancer is colon cancer.

4. The method according to claim 1 , wherein said cancer is small cell lung cancer.

5. The method according to claim 1 , wherein said cancer is liver cancer.

6. The method according to claim 1 , wherein said cancer is breast cancer.

7. A method of inducing androgen receptor antagonist activity, said method comprising contacting a cell with an androgen receptor antagonist effective amount of a compound having the following structure:

or a pharmaceutically acceptable salt thereof.

8. The method according to claim 7 , wherein said contacting step is carried out in vivo.

9. The method according to claim 7 , wherein said contacting step is carried out in vitro.

10. A method of inducing androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction, said method comprising administering an effective amount of a compound having the following structure:

or a pharmaceutically acceptable salt thereof wherein said androgen-related affliction is selected from the group consisting of baldness, hirsutism and acne.

11. The method according to claim 10 , wherein said subject is afflicted with baldness.

12. The method according to claim 10 , wherein said subject is afflicted with hirsutism.

13. The method according to claim 10 , wherein said subject is afflicted with acne.

14. The method of claim 1 , wherein said cancer is selected from the group consisting of small cell lung cancer, colon cancer, breast cancer, and prostate cancer.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 12, 2018
From: UNIV OF NORTH CAROLINA CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045307/0381 →
Continuity (3)
Continuation 12030678 · Feb 13, 2008
Continuation In Part 10966723 · Oct 15, 2004
Related Publication 20100197784A1 · Aug 5, 2010